A unique independent nationwide observational study in EU member state Hungary estimating and directly comparing efficacy of five vaccines against COVID has demonstrated that the Russian Sputnik V vaccine has the highest (98%) efficacy in preventing COVID-related mortality and 85.7% efficacy against coronavirus infection leading alongside the vaccine by Moderna. The study based on the […]
The Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund) today announced the Russian single-component Sputnik Light vaccine against coronavirus has been approved by the Egyptian Drug Authority (EDA).Sputnik Light vaccine is based on human adenovirus serotype 26 which is the first component of the Sputnik V vaccine. Immunization with Sputnik Light in Egypt will […]
The Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund) announces the real world data of the Ministry of Health of the Republic of Belarus on the Russian Sputnik V coronavirus vaccine confirming its high efficacy during the vaccination campaign in the country. The Russian vaccine has demonstrated 97.2% efficacy against coronavirus in Belarus. The […]
The Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund) announces results of a study in Argentina with authors noting that protection against coronavirus increases over 6 months following vaccination with the Russian Sputnik V vaccine as a consequence of antibody maturation, resulting in improved potency of antibodies to viral escape mutations. The study results […]
The Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund) announces the approval of the Russian Sputnik V vaccine against coronavirus in the Republic of Indonesia. Indonesia has become the 70th country in the world to register the Russian vaccine. Sputnik V was granted an emergency use authorization. Total population of all countries where Sputnik […]
The Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund) announces the initial safety results of the randomized, single-blind study for the evaluation of the immune response and safety of heterogeneous regimens combining the first component of the Russian Sputnik V vaccine against coronavirus (Sputnik Light vaccine based on human adenovirus serotype 26) and vaccines […]
The Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund) and Argentina’s Laboratorios Richmond SACIF pharmaceutical company today announced the Sputnik V vaccine produced at Company’s facilities will become available for vaccination in Argentina starting from this week following successful quality control of test samples at the Gamaleya Center on August 3. Sucessful start of […]
The Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund) announces initial safety results of the world’s first study of a combination between the AstraZeneca vaccine (developed jointly with the University of Oxford) and the first component of the Sputnik V vaccine (Sputnik Light vaccine based on human adenovirus serotype 26) in the Republic of […]
The Gamaleya National Research Center of Epidemiology and Microbiology and the Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund) today announced strong results of the study on neutralizing activity of sera from individuals vaccinated with Sputnik V vaccine against new variants of SARS-CoV-2. Vaccination with Sputnik V has produced protective neutralizing titers against new […]
